Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk

  • Harold Bays
  • Helena W. Rodbard
  • Alan Bruce Schorr
  • J. Michael González-Campoy

Opinion statement

Excessive adipose tissue is potentially pathogenic due to its mass effects and through adverse metabolic/immune responses, which may lead to cardiovascular disease risk factors (eg, type 2 diabetes mellitus, hypertension, dyslipidemia, and possibly atherosclerosis itself). Positive caloric balance in genetically/environmentally susceptible patients may result in adipocyte hypertrophy, visceral adipose tissue accumulation, and ectopic fat deposition, all causally associated with metabolic disease, and all anatomic manifestations of “adiposopathy” (a term used to describe adipose tissue pathology). Weight loss through improved nutrition, increased physical activity, and weight loss agents (ie, orlistat and sibutramine) improves adiposopathy and improves many metabolic diseases whose prevalence are directly associated with an increase in body fat and sedentary lifestyle. Cannabinoid receptor antagonists improve adiposopathy through weight reduction and favorable metabolic effects upon multiple body organs (including adipocytes). Peroxisome proliferator-activated receptor-γ agonists may improve adiposopathy through recruitment of functional fat cells and apoptosis of dysfunctional fat cells.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Bays H, Ballantyne C: Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol 2006, 1:389–420.CrossRefGoogle Scholar
  2. 2.
    World Health Organization: Global Strategy on Diet, Physical Activity and Health. Available at Accessed November 19, 2005.
  3. 3.
    Bays H, Chapman R, Grandy S: The relationship of body mass index to diabetes mellitus, hypertension, and dyslipidemia: comparison of data of two national surveys. Int J Clin Pract 2007, 61:737–747.PubMedCrossRefGoogle Scholar
  4. 4.
    Bays H, Abate N, Chandalia M: Adiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiol 2005, 1:39–59.CrossRefPubMedGoogle Scholar
  5. 5.
    Bays H: Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev Cardiovasc Ther 2005, 3:393–404.PubMedCrossRefGoogle Scholar
  6. 6.
    Bays H, Blonde L, Rosenson R: Adiposopathy: how do diet, exercise, weight loss and drug therapies improve metabolic disease? Expert Rev Cardiovasc Ther 2006, 4:871–895.PubMedCrossRefGoogle Scholar
  7. 7.
    Bays HE: Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004, 12:1197–1211.PubMedGoogle Scholar
  8. 8.
    Bays H: Adiposopathy: defining, diagnosing, and establishing indications to treat “sick fat”: what are the regulatory considerations? US Endocrine Disease 2006, 2:12–14.Google Scholar
  9. 9.
    Bays H, Dujovne CA: Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep 2006, 8:144–156.PubMedCrossRefGoogle Scholar
  10. 10.
    Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548–2556.PubMedCrossRefGoogle Scholar
  11. 11.
    Schaffler A, Muller-Ladner U, Scholmerich J, Buchler C: Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 2006, 27:449–467.PubMedCrossRefGoogle Scholar
  12. 12.
    Anderson JW, Kendall CW, Jenkins DJ: Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003, 22:331–339.PubMedGoogle Scholar
  13. 13.
    Henry RR, Gumbiner B: Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 1991, 14:802–823.PubMedCrossRefGoogle Scholar
  14. 14.
    Viguerie N, Vidal H, Arner P, et al.: Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets. Diabetologia 2005, 48:123–131.PubMedCrossRefGoogle Scholar
  15. 15.
    Hamman RF, Wing RR, Edelstein SL, et al.: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006, 29:2102–2107.PubMedCrossRefGoogle Scholar
  16. 16.
    Diaz VA, Player MS, Mainous AG 3rd, et al.: Competing impact of excess weight versus cardiorespiratory fitness on cardiovascular risk. Am J Cardiol 2006, 98:1468–1471.PubMedCrossRefGoogle Scholar
  17. 17.
    Larson-Meyer DE, Heilbronn LK, Redman LM, et al.: Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 2006, 29:1337–1344.PubMedCrossRefGoogle Scholar
  18. 18.
    Bassuk SS, Manson JE: Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol 2005, 99:1193–1204.PubMedCrossRefGoogle Scholar
  19. 19.
    Astrup A, Finer N: Redefining type 2 diabetes: ‘diabesity’ or ‘obesity dependent diabetes mellitus’? Obes Rev 2000, 1:57–59.PubMedCrossRefGoogle Scholar
  20. 20.
    Avenell A, Brown TJ, McGee MA, et al.: What are the long-term benefits of weight reducing diets in adults? A system atic review of randomized controlled trials. J Hum Nutr Diet 2004, 17:317–335.PubMedCrossRefGoogle Scholar
  21. 21.
    Eckel RH: The dietary approach to obesity: is it the diet or the disorder? JAMA 2005, 293:96–97.PubMedCrossRefGoogle Scholar
  22. 22.
    Hansen D, Dendale P, Berger J, et al.: The effects of exercise training on fat-mass loss in obese patients during energy intake restriction. Sports Med 2007, 37:31–46.PubMedCrossRefGoogle Scholar
  23. 23.
    Clifton P: The science behind weight loss diets—a brief review. Aust Fam Physician 2006, 35:580–582.PubMedGoogle Scholar
  24. 24.
    Rating the diets from Atkins(TM) to Dr. Sears Zone [no authors listed]. Consum Rep 2005, 70:18–22.Google Scholar
  25. 25.
    Tsai AG, Wadden TA: Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med 2005, 142:56–66.PubMedGoogle Scholar
  26. 26.
    Bays H, Mandarino L, DeFronzo RA: Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004, 89:463–478.PubMedCrossRefGoogle Scholar
  27. 27.
    Loviscach M, Henry RR: Clinical significance of peroxisome proliferator-activated receptors in health and disease. Available at Accessed April 19, 2007.
  28. 28.
    Meridia US Prescribing Information and Patient Information. Available at Accessed February 20, 2007.
  29. 29.
    Bays H: Adiposopathy: the endocannabinoid system as a therapeutic treatment target for dysfunctional “sick” fat. California J Health System Pharmacy 2007, 19:32–39.Google Scholar
  30. 30.
    Anghelescu I, Klawe C, Szegedi A: Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior. J Clin Psychopharmacol 2002, 22:521–524.PubMedCrossRefGoogle Scholar
  31. 31.
    Aydin N, Topsever P, Kaya A, et al.: Orlist at, sibutramine, or combination therapy: which performs better on waist circum ference in relation with body mass index in obese patients? Tohoku J Exp Med 2004, 202:173–180.PubMedCrossRefGoogle Scholar
  32. 32.
    Kaya A, Aydin N, Topsever P, et al.: Efficacy of sibutramine, orlist at and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004, 58:582–587.PubMedCrossRefGoogle Scholar
  33. 33.
    Wadden TA, Berkowitz RI, Womble LG, et al.: Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000, 8:431–437.PubMedGoogle Scholar
  34. 34.
    Sari R, Balci MK, Cakir M, et al.: Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 2004, 30:159–167.PubMedCrossRefGoogle Scholar
  35. 35.
    Whigham LD, Dhurandhar NV, Rahko PS, Atkinson RL: Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status. Int J Obes (Lond) 2007, 31:850–857.Google Scholar
  36. 36.
    Gardin JM, Schumacher D, Constantine G, et al.: Valvular abnorm alities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000, 283:1703–1709.PubMedCrossRefGoogle Scholar
  37. 37.
    Gardin JM, Constantine G, Davis K, et al.: Aortic valvular regurgitation: prevalence and clinical characteristics in a predominantly obese adult population not taking anorexigens. Echocardiography 2006, 23:569–576.PubMedCrossRefGoogle Scholar
  38. 38.
    Halford JC, Harrold JA, Boyland EJ, et al.: Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007, 67:27–55.PubMedCrossRefGoogle Scholar
  39. 39.
    Smith SR, Prosser W, Donahue D, et al.: Lorcaserin (APD356), a Selective 5-HT2C Agonist, Safely Induces Weight Loss in a 12-week Study of Healthy Obese Patients. Paper presented at the American Diabetes Association 66th Annual Scientific Sessions. Washington, DC; June 12, 2006.Google Scholar
  40. 40.
    Masaki T, Chiba S, Yasuda T, et al.: Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004, 53:2250–2260.PubMedCrossRefGoogle Scholar
  41. 41.
    Takahashi K, Suwa H, Ishikawa T, Kotani H: Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J Clin Invest 2002, 110:1791–1799.PubMedCrossRefGoogle Scholar
  42. 42.
    Poyurovsky M, Pashinian A, Levi A, et al.: The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol 2005, 20:101–103.PubMedCrossRefGoogle Scholar
  43. 43.
    Kopelman P, Bryson A, Hickling R, et al.: Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007, 31:494–499.CrossRefGoogle Scholar
  44. 44.
    Bays H: The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy. Drugs R D 2006, 7:289–302.PubMedCrossRefGoogle Scholar
  45. 45.
    Erondu N, Gantz I, Musser B, et al.: Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006, 4:275–282.PubMedCrossRefGoogle Scholar
  46. 46.
    Genaer a Press Release: Genaera Corporation Announces Presentation of Data on Trodusquemine Mechanism of Action in Obesity. Available at Accessed January 16, 2007.
  47. 47.
    Pissios P, Maratos-Flier E: Melanin-concentrating hormone: from fish skin to skinny mammals. Trends Endocrinol Metab 2003, 14:243–248.PubMedCrossRefGoogle Scholar
  48. 48.
    Tavares FX, Al-Barazanji KA, Bigham EC, et al.: Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1. J Med Chem 2006, 49:7095–7107.PubMedCrossRefGoogle Scholar
  49. 49.
    Young A, Denaro M: Roles of amylin in diabetes and in regulation of nutrient load. Nutrition 1998, 14:524–527.PubMedCrossRefGoogle Scholar
  50. 50.
    Chapman I, Parker B, Doran S, et al.: Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005, 48:838–848.PubMedCrossRefGoogle Scholar
  51. 51.
    Gadde DM, Yonish GM, Foust MS, et al.: A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, in obese adults. Program and abstracts of the Annual Scientific Meeting of NAASO, The Obesity Society. Boston, MA; October 20–24, 2006. Abstract 55-OR.Google Scholar
  52. 52.
    Greenway F, Anderson J Atkinson R et al.: Bupropion and zonisamide for the treatment of obesity. Program and abstracts of the Annual Scientific Meeting of NAASO, The Obesity Society. Boston, MA; October 20–24, 2006. Abstract 52-OR.Google Scholar
  53. 53.
    Orexigen: Clinical Trials—Data. Available at Accessed February 4, 2007.
  54. 54.
    Gregoire F, Genart C, Hauser N, Remacle C: Glucocorticoids induce a drastic inhibition of proliferation and stimulate differentiation of adult rat fat cell precursors. Exp Cell Res 1991, 196:270–278.PubMedCrossRefGoogle Scholar
  55. 55.
    Tomlinson JW, Walker EA, Bujalska IJ, et al.: 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004, 25:831–866.PubMedCrossRefGoogle Scholar
  56. 56.
    Bujalska IJ, Kumar S, Stewart PM: Does central obesity reflect “Cushing’s disease of the omentum”? Lancet 1997, 349:1210–1213.PubMedCrossRefGoogle Scholar
  57. 57.
    Salans LB, Bray GA, Cushman SW, et al.: Glucose metabolism and the response to insulin by human adipose tissue in spontaneous and experimental obesity. Effects of dietary composition and adipose cell size. J Clin Invest 1974, 53:848–856.PubMedCrossRefGoogle Scholar
  58. 58.
    Bray GA, Glennon JA, Salans LB, et al.: Spontaneous and experimental human obesity: effects of diet and adipose cell size on lipolysis and lipogenesis. Metabolism 1977, 26:739–747.PubMedCrossRefGoogle Scholar
  59. 59.
    Ravussin E, Smith SR: Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 2002, 967:363–378.PubMedCrossRefGoogle Scholar
  60. 60.
    John-Soway J: Implications of Viewing Obesity as a Disease. Available at Accessed February 28, 2007.

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Harold Bays
    • 1
  • Helena W. Rodbard
  • Alan Bruce Schorr
  • J. Michael González-Campoy
  1. 1.L-MARC Research CenterLouisvilleUSA

Personalised recommendations